共 50 条
- [21] ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)Wainberg, Zev A.Wang, LanYue, HuibinMotwani, MonicaKasichayanula, SreeneeranjBlaney, Martha ElizabethNaumovski, LouieStrickler, John H.
- [22] Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancerBritish Journal of Cancer, 2019, 121 : 429 - 430Vera GorbunovaJ. Thaddeus BeckRalf-Dieter HofheinzPilar Garcia-AlfonsoMarina NechaevaAntonio Cubillo GracianLaszlo MangelElena Elez FernandezDustin A. DemingRamesh K. RamanathanAlison H. TorresDanielle SullivanYan LuoJordan D. Berlin
- [23] Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI plus cetuximab / bevacizumab (FIRE-3 trial).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Stahler, ArndtStintzing, SebastianModest, Dominik PaulJelas, IvanHeinrich, KathrinMiller-Phillips, Lisavon Einem, Jobst C.Vehling-Kaiser, UrsulaDecker, ThomasKiani, Alexandervon Weikersthal, Ludwig FischerHeintges, TobiasKahl, ChristophKullmann, FrankScheithauer, WernerMoehler, Markus H.Wirapati, PratyakshaKirchner, ThomasJung, AndreasHeinemann, Volker
- [24] Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancerANNALS OF ONCOLOGY, 2023, 34 : S438 - S438Bond, M. J. G.van Smeden, M.Degeling, K.Cremolini, C.Schmoll, H. J. E-V.Rossini, D.Ibach, S.Koopman, M.Punt, C. J. A.May, A. M.Kwakman, J. J.
- [25] Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID)CANCER MEDICINE, 2024, 13 (07):Arai, HiroyukiTsuda, TakashiSunakawa, YuShimokawa, MototsuguAkiyoshi, KoheiTokunaga, ShinyaShoji, HirokazuKunieda, KenjiKotaka, MasahitoMatsumoto, ToshihikoNagata, YusukeMizukami, TakuroMizuki, FumitakaDanenberg, Kathleen D.Boku, NarikazuNakajima, Takako Eguchi
- [26] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial (vol 17, pg 1426, 2016)LANCET ONCOLOGY, 2016, 17 (10): : E420 - E420Stintzing, S.Modest, D. P.Rossius, L.
- [27] Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Heinemann, Volkervon Weikersthal, Ludwig FischerDecker, ThomasKiani, AlexanderVehling-Kaiser, UrsulaAl-Batran, Salah-EddinHeintges, TobiasLerchenmueller, JuergenKahl, ChristophSeipelt, GernotKullmann, FrankStauch, MartinaScheithauer, WernerHielscher, JoergScholz, MichaelMueller, SebastianSchaefer, BrittaModest, Dominik PaulJung, AndreasStintzing, Sebastian
- [28] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial (vol 17, pg 1426, 2016)LANCET ONCOLOGY, 2016, 17 (11): : E479 - E479Stintzing, S.Modest, D. P.Rossius, L.
- [29] About RAS Mutation Clearance in Plasma ctDNA From RAS-Mutant Colorectal Cancer PatientsJCO PRECISION ONCOLOGY, 2021, 5 : 389 - 390Gazzaniga, PaolaNicolazzo, ChiaraCaponnetto, SalvatoreCortesi, Enrico
- [30] CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC).JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Ziras, N.Polyzos, A.Xenidis, N.Kalykaki, A.Androulakis, N. E.Papakotoulas, P.Kentepozidis, N. K.Makrantonakis, P.Xynogalos, S.Sougklakos, I.